Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
PODD enters its November 4 earnings print carrying two contradictory signals: short interest has jumped nearly 50% over the past month, yet the CEO bought stock in August and Barclays just initiated coverage this week. The tension between a rebuilding short position and fresh institutional and executive-level interest makes this one of the more charged setups in med-tech right now.
The short positioning deserves attention. Short interest has risen to 7.2% of free float, up from roughly 4.9% in early September, a 46% increase in under six weeks. That is a meaningful build, concentrated almost entirely in the window that followed the August earnings miss. The short score has drifted lower over the past ten days, easing from 43.3 to 42.3, suggesting the pace of new short-selling has slowed this week. The borrow market tells a similar story of manageable pressure: cost to borrow is just 0.43% and availability is extraordinarily loose at nearly 9,800%, far above the 52-week low of 2,187%. There is no squeeze dynamic at play. Options positioning has softened slightly from its recent cautious levels, with the put/call ratio at 1.08, below its 20-day average of 1.15, the least defensive reading in several weeks.
The Street is split, and the August earnings report is the fault line. After Insulet delivered Q2 revenue of $801.7 million with management cutting U.S. Omnipod growth guidance to 17% to 19% from 20% to 22%, most analysts slashed targets aggressively. TD Cowen dropped its target from $294 to $144. Wells Fargo downgraded from Overweight to Equal-Weight and cut from $255 to $144. Leerink downgraded to Market Perform and moved its target to $145. Bulls, including Stifel and Benchmark, kept Buy ratings but trimmed to $180 and $185 respectively, citing the 72.9% gross margin and the Omnipod 5 and future Omnipod 6 pipeline. The bear case centres on U.S. Type 2 retention weakness, first-90-day churn, GLP-1 pressure on insulin needs, and the near-total revenue concentration in a single product. Barclays initiated this week with Equal-Weight and a $150 target, broadly in line with the cautious consensus. The mean analyst target of $171 implies around 27% upside from current levels, though that figure is anchored by bulls who have not revisited their models since August. The consensus sits at Hold, and the forward earnings picture has weakened, with the 12-month forward EPS growth factor ranking in the 23rd percentile of the universe.
The most differentiated signal may be in insider activity. CEO Ashley McEvoy bought 1,100 shares on the open market on August 21 at $147.47, committing $162,000 without a 10b5-1 plan in place. That is a discretionary purchase, made into weakness roughly two weeks after the earnings-driven selloff. Director Timothy Stonesifer added 2,790 shares at $143.51 in early June, also without a plan. Net insider buying over the 90-day period covered by SEC filings amounts to just over $162,000, limited to the CEO transaction, but the absence of any open-market selling by senior management adds a modest counterweight to the bearish positioning. The compensation-related awards and tax withholding transactions by other insiders carry no sentiment signal.
On the institutional side, BlackRock added 314,000 shares in its most recent reported period to hold 9.6% of the company. State Street also added modestly. The activist register carries a notable entry: The Vanguard Group filed a 13G/A in March showing a stake of 0%, down from a prior 12.49% disclosed position, which under the as-last-disclosed rule means Vanguard's original group entity may have substantially reduced its holding. A separate Vanguard Capital Management entity filed a new 13G in April at 7.49%. Capital Research Global Investors disclosed a reduction from 6.7% to 2.4%, and FMR (Fidelity) dropped from 5.6% to 1.4% as of August. These are meaningful outflows from large, long-oriented holders in the months following the guidance cut, and they sit alongside the short rebuild in the same period.
Insulet's last four reported earnings prints show a -16.5% one-day move on the August result and a +5.9% one-day move on the prior quarter's release. The record is uneven, and with the next print four weeks away, the question heading into November is whether management can demonstrate that U.S. Type 2 retention is stabilising, rather than whether international growth remains intact.
See the live data behind this article on ORTEX.
Open PODD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
